International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.8053859
Original Article
Newly Diagnosed Patient with Anti-Hmgcoa Antibody- Associated Necrotizing Autoimmune Myopathy (Immune-Mediated Necrotizing Myopathy IMNM)
 ,
 ,
Published
June 19, 2023
Abstract
Anti- HMGR antibody positive immune mediated necrotizing myopathy is a rare disease was first recognized and characterised in patients with a history of stating exposure and immune -mediated necrotizing myopathy. We reported a rare case of patient presenting with features of proximal myopathy which has a wide differential diagnoses of which a diagnosis of anti- HMGCR-antibody associated myopathy should not be neglected. Effective treatment can Improve the prognosis if diagnosed in time, We provide a summary of clinical findings, pathological features, muscle imaging and immunogenetic risk factors of the disease. We also discuss treatment strategies and approaches to monitoring the therapeutic response. lastly, we briefly summaries the current understanding of the pathophysiology of the disease and postulate a mode for autoimmunity initiation and propagation in the disease.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
2796 Views
297 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved